Cerus Corp CERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.32
- Day Range
- $2.26–2.37
- 52-Week Range
- $1.38–3.47
- Bid/Ask
- $2.30 / $2.37
- Shares Outstanding
- 201.52M
- Market Cap
- $459.48M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 44.37
- Price/Sales
- 2.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 345
- Website
- https://www.cerus.com
Valuation
|
Metric
|
CERS
|
|---|---|
Price/Earnings (Normalized) | 44.37 |
Price/Book Value | 6.67 |
Price/Sales | 2.04 |
Price/Cash Flow | 24.93 |
Price/Earnings
CERS
Financial Strength
|
Metric
|
CERS
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.83 |
Interest Coverage | 0.16 |
Quick Ratio
CERS
Profitability
|
Metric
|
CERS
|
|---|---|
Return on Assets (Normalized) | 4.26% |
Return on Equity (Normalized) | 14.41% |
Return on Invested Capital (Normalized) | 9.64% |
Return on Assets
CERS
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|@jnQ@W! | LOCK|^^TK | $169B | |||
| Medtronic PLC
MDT
| LOCK|@LGQCff | LOCK|KlMX | $110B | |||
| Stryker Corp
SYK
| LOCK|xg##L>< | LOCK|%p | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|qy<Q>># | LOCK|f&nZ | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|pVnp<&^s | LOCK|JZsQ# | $49B | |||
| DexCom Inc
DXCM
| LOCK|W^Rdq@!s | LOCK|%bp< | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|@>??#M | LOCK|>C | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|>T | LOCK|hQ | $23B | |||
| Steris PLC
STE
| LOCK|^WBmRFJ | LOCK|JDY$ | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|?vy%xvWZ | LOCK|%>m | $17B |
United States